Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.  [electronic resource] 

 -  Nature medicine  11 2016 
 - 1314-1320 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1546-170X 
<br/><br/><label>Standard No.: </label>10.1038/nm.4204  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Anilides--pharmacology<br/>Animals<br/>Brain Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Child<br/>Child, Preschool<br/>Crizotinib<br/>DNA, Neoplasm<br/>Female<br/>Glioblastoma--drug therapy<br/>Humans<br/>Infant<br/>Male<br/>Mice<br/>Mice, SCID<br/>Microtubule-Associated Proteins--genetics<br/>Mitogen-Activated Protein Kinases<br/>Oncogene Proteins, Fusion--genetics<br/>Protein Kinase Inhibitors--pharmacology<br/>Proteins--genetics<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Pyrazoles--therapeutic use<br/>Pyridines--therapeutic use<br/>Quinolines--pharmacology<br/>RNA, Messenger--metabolism<br/>Receptor-Like Protein Tyrosine Phosphatases, Class 5--genetics<br/>Sequence Analysis, DNA<br/>Signal Transduction<br/>Xenograft Model Antitumor Assays<br/>Young Adult